Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Residual hormone levels in used contraceptive rings as a measurement of adherence to vaginal ring use.

Haaland RE, Holder A, Evans-Strickfaden T, Nyagol B, Makanga M, Oyaro B, Humwa F, Williams T, McLellan-Lemal E, Desai M, Huey MJ.

Contraception. 2017 Jun;95(6):602-604. doi: 10.1016/j.contraception.2017.03.011. Epub 2017 Apr 1.

2.

Progesterone Levels Associate with a Novel Population of CCR5+CD38+ CD4 T Cells Resident in the Genital Mucosa with Lymphoid Trafficking Potential.

Swaims-Kohlmeier A, Haaland RE, Haddad LB, Sheth AN, Evans-Strickfaden T, Lupo LD, Cordes S, Aguirre AJ, Lupoli KA, Chen CY, Ofotukun I, Hart CE, Kohlmeier JE.

J Immunol. 2016 Jul 1;197(1):368-76. doi: 10.4049/jimmunol.1502628. Epub 2016 May 27.

3.

Self-collected genital swabs compared with cervicovaginal lavage for measuring HIV-1 and HSV-2 and the effect of acyclovir on viral shedding.

McNicholl JM, Leelawiwat W, Whitehead S, Hanson DL, Evans-Strickfaden T, Cheng CY, Chonwattana W, Mueanpai F, Kittinunvorakoon C, Markowitz L, Dunne EF.

Int J STD AIDS. 2017 Mar;28(4):372-379. doi: 10.1177/0956462416650123. Epub 2016 Jul 10.

4.

HIV-1 genital shedding is suppressed in the setting of high genital antiretroviral drug concentrations throughout the menstrual cycle.

Sheth AN, Evans-Strickfaden T, Haaland R, Martin A, Gatcliffe C, Adesoye A, Omondi MW, Lupo LD, Danavall D, Easley K, Chen CY, Pau CP, Hart C, Ofotokun I.

J Infect Dis. 2014 Sep 1;210(5):736-44. doi: 10.1093/infdis/jiu166. Epub 2014 Mar 18.

5.

Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties.

Mesquita PM, Srinivasan P, Johnson TJ, Rastogi R, Evans-Strickfaden T, Kay MS, Buckheit KW, Buckheit RW Jr, Smith JM, Kiser PF, Herold BC.

Retrovirology. 2013 Oct 24;10:113. doi: 10.1186/1742-4690-10-113.

6.

Carrageenan-based gel retains limited anti-HIV-1 activity 8-24 hours after vaginal application by HIV-infected Thai women enrolled in a phase I safety trial.

Haaland RE, Chaowanachan T, Evans-Strickfaden T, van de Wijgert JH, Kilmarx PH, McLean CA, Hart CE.

J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):e71-3. doi: 10.1097/QAI.0b013e318271c8f9. No abstract available.

7.

HIV-1 and herpes simplex virus type-2 genital shedding among co-infected women using self-collected swabs in Chiang Rai, Thailand.

Forhan SE, Dunne EF, Sternberg MR, Whitehead SJ, Leelawiwat W, Thepamnuay S, Chen C, Evans-Strickfaden T, McNicholl JM, Markowitz LE.

Int J STD AIDS. 2012 Aug;23(8):560-4. doi: 10.1258/ijsa.2012.011295.

PMID:
22930292
8.

UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application.

Haaland RE, Evans-Strickfaden T, Holder A, Pau CP, McNicholl JM, Chaikummao S, Chonwattana W, Hart CE.

Antimicrob Agents Chemother. 2012 Jul;56(7):3592-6. doi: 10.1128/AAC.00452-12. Epub 2012 Apr 16.

9.

Female genital tract shedding of CXCR4-tropic HIV Type 1 is associated with a majority population of CXCR4-tropic HIV Type 1 in blood and declining CD4(+) cell counts.

Haaland RE, Sullivan ST, Evans-Strickfaden T, Lennox JL, Hart CE.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1524-32. doi: 10.1089/AID.2012.0004. Epub 2012 Mar 23.

10.

Role of donor genital tract HIV-1 diversity in the transmission bottleneck.

Boeras DI, Hraber PT, Hurlston M, Evans-Strickfaden T, Bhattacharya T, Giorgi EE, Mulenga J, Karita E, Korber BT, Allen S, Hart CE, Derdeyn CA, Hunter E.

Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):E1156-63. doi: 10.1073/pnas.1103764108. Epub 2011 Nov 7.

11.

HIV-1 RNA rectal shedding is reduced in men with low plasma HIV-1 RNA viral loads and is not enhanced by sexually transmitted bacterial infections of the rectum.

Kelley CF, Haaland RE, Patel P, Evans-Strickfaden T, Farshy C, Hanson D, Mayer K, Lennox JL, Brooks JT, Hart CE.

J Infect Dis. 2011 Sep 1;204(5):761-7. doi: 10.1093/infdis/jir400.

12.

Lack of effect of compartmentalized drug resistance mutations on HIV-1 pol divergence in antiretroviral-experienced women.

Kelley CF, Sullivan ST, Lennox JL, Evans-Strickfaden T, Hart CE.

AIDS. 2010 Jun 1;24(9):1361-6. doi: 10.1097/QAD.0b013e3283394f3f.

PMID:
20389234
13.

Mucosal innate immune factors in the female genital tract are associated with vaginal HIV-1 shedding independent of plasma viral load.

Cummins JE, Christensen L, Lennox JL, Bush TJ, Wu Z, Malamud D, Evans-Strickfaden T, Siddig A, Caliendo AM, Hart CE, Dezzutti CS.

AIDS Res Hum Retroviruses. 2006 Aug;22(8):788-95.

PMID:
16910835
14.
15.

Detection of infectious human immunodeficiency virus type 1 in female genital secretions by a short-term culture method.

Cummins JE Jr, Villanueva JM, Evans-Strickfaden T, Sesay SM, Abner SR, Bush TJ, Green TA, Lennox JL, Wright T, Folks TM, Hart CE, Dezzutti CS.

J Clin Microbiol. 2003 Sep;41(9):4081-8.

16.

The menstrual cycle does not affect human immunodeficiency virus type 1 levels in vaginal secretions.

Villanueva JM, Ellerbrock TV, Lennox JL, Bush TJ, Wright TC, Pratt-Palmore M, Evans-Strickfaden T, Conley LJ, Schnell C, Hart CE.

J Infect Dis. 2002 Jan 15;185(2):170-7. Epub 2002 Jan 3.

PMID:
11807690
17.

Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions.

Ellerbrock TV, Lennox JL, Clancy KA, Schinazi RF, Wright TC, Pratt-Palmore M, Evans-Strickfaden T, Schnell C, Pai R, Conley LJ, Parrish-Kohler EE, Bush TJ, Tatti K, Hart CE.

J Infect Dis. 2001 Jul 1;184(1):28-36. Epub 2001 May 30.

PMID:
11398106
18.

Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration.

Wright TC Jr, Subbarao S, Ellerbrock TV, Lennox JL, Evans-Strickfaden T, Smith DG, Hart CE.

Am J Obstet Gynecol. 2001 Feb;184(3):279-85.

PMID:
11228474
19.

Rapid CD4(+) T-cell loss induced by human immunodeficiency virus type 1(NC) in uninfected and previously infected chimpanzees.

Novembre FJ, de Rosayro J, Nidtha S, O'Neil SP, Gibson TR, Evans-Strickfaden T, Hart CE, McClure HM.

J Virol. 2001 Feb;75(3):1533-9. Erratum in: J Virol 2001 Jun;75(11):5441.

20.

Progressive infection in a subset of HIV-1-positive chimpanzees.

O'Neil SP, Novembre FJ, Hill AB, Suwyn C, Hart CE, Evans-Strickfaden T, Anderson DC, deRosayro J, Herndon JG, Saucier M, McClure HM.

J Infect Dis. 2000 Oct;182(4):1051-62. Epub 2000 Sep 8.

PMID:
10979899
21.

Correlation between human immunodeficiency virus type 1 RNA levels in the female genital tract and immune activation associated with ulceration of the cervix.

Lawn SD, Subbarao S, Wright TC Jr, Evans-Strickfaden T, Ellerbrock TV, Lennox JL, Butera ST, Hart CE.

J Infect Dis. 2000 Jun;181(6):1950-6. Epub 2000 May 31.

PMID:
10837174
22.

Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract.

Hart CE, Lennox JL, Pratt-Palmore M, Wright TC, Schinazi RF, Evans-Strickfaden T, Bush TJ, Schnell C, Conley LJ, Clancy KA, Ellerbrock TV.

J Infect Dis. 1999 Apr;179(4):871-82.

PMID:
10068582
23.
24.
25.

Endotoxin removal using 6,000 molecular weight cut-off polyacrylonitrile (PAN) and polysulfone (PS) hollow fiber ultrafilters.

Evans-Strickfaden TT, Oshima KH, Highsmith AK, Ades EW.

PDA J Pharm Sci Technol. 1996 May-Jun;50(3):154-7.

PMID:
8696778
26.

The removal of phages T1 and PP7, and poliovirus from fluids with hollow-fiber ultrafilters with molecular weight cut-offs of 50,000, 13,000, and 6000.

Oshima KH, Evans-Strickfaden TT, Highsmith AK, Ades EW.

Can J Microbiol. 1995 Apr-May;41(4-5):316-22.

PMID:
8590412

Supplemental Content

Loading ...
Support Center